Myelofibrosis Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Myelofibrosis Treatment Market Trends and Insights

Increasing Adoption of Phenotype-Specific JAK Inhibitor Therapy

Treatment selection in the myelofibrosis treatment market is shifting toward a phenotype-based approach. Anemia severity, platelet count, and treatment history increasingly guide therapy selection. Momelotinib inhibits JAK1, JAK2, and ACVR1, lowering hepcidin levels, supporting erythropoiesis, and addressing splenomegaly. Published treatment guidance positions pacritinib for patients with platelet counts below 50 × 10⁹/L and momelotinib for transfusion-dependent patients, creating clearer clinical roles for approved JAK inhibitors.

Pipeline Expansion of Disease-Modifying and Combination Therapies

Combination therapy programs are expanding options in the myelofibrosis treatment market. In the 2025 MANIFEST-2 trial, pelabresib plus ruxolitinib achieved SVR35 in 65.9% of JAK inhibitor-naive patients, compared with 35.2% for ruxolitinib alone. Selinexor plus ruxolitinib achieved SVR35 in 47% of patients at week 36, compared with 23% in the comparator group.^{[1]Tarabishy, Y., et al., “Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis: A Randomized Phase 3 Trial,” Nature Medicine, link.springer.com} Karyopharm submitted a supplemental New Drug Application for the combination in August 2026 and sought accelerated approval. Imetelstat showed a median overall survival of 30.7 months versus 15.4 months with best-available therapy in an updated post-hoc matched analysis presented at ASCO 2026. These programs cover BET inhibition, XPO1 blockade, MDM2 activation, telomerase inhibition, and Type II JAK2 selectivity for frontline and later-line care.

Expansion of Anemia-Directed Treatment Options

Anemia remains a significant unmet need in myelofibrosis treatment and may worsen during ruxolitinib therapy. The Phase 2 ODYSSEY trial enrolled its first patient in February 2025 to evaluate momelotinib plus luspatercept in transfusion-dependent disease. The combination targets early and late stages of erythropoiesis through complementary SMAD pathway activity. In the Phase 2 RESTORE trial, elritercept achieved transfusion independence in 30.4% of transfusion-dependent patients and reduced transfusion burden by at least 50% in 73% of patients requiring at least 3 red blood cell units per 12 weeks at week 24. The 2025 INDEPENDENCE trial failed to meet its primary endpoint for luspatercept, increasing development interest in JAK inhibitor combinations with complementary erythropoietic mechanisms.^{[2]Perla, A., et al., “Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs,” PubMed Central, pmc.ncbi.nlm.nih.gov}

Growing Demand for Post-JAK Inhibitor Treatment

The post-JAK inhibitor setting remains underserved in the myelofibrosis treatment market. Historical median survival after ruxolitinib discontinuation was 13.2 months before later-line JAK inhibitors became available. Even with sequential JAK inhibitor use, many patients exhaust approved options within 3 to 5 years. IMPACTMF, BOREAS, and the confirmatory SENTRY program target patients with inadequate responses after JAK inhibitor treatment. Ipsen completed its acquisition of Kartos Therapeutics in August 2026, adding navtemadlin, an MDM2 inhibitor under evaluation for TP53 wild-type patients with a suboptimal ruxolitinib response. These developments may differentiate later-line care through mechanisms such as TP53 pathway restoration and renewed JAK pathway targeting.

Treatment-Limiting Anemia, Thrombocytopenia, and Myelosuppression

Myelosuppression remains a key safety challenge in JAK inhibitor treatment and can limit dose escalation for patients requiring more intensive therapy. In MANIFEST-2, 52.8% of patients receiving pelabresib plus ruxolitinib experienced thrombocytopenia, while 44.8% experienced anemia of any grade. In the SENTRY trial, thrombocytopenia occurred in 59% of the selinexor plus ruxolitinib group, compared with 43% of the ruxolitinib plus placebo group. Dose reductions to manage hematologic toxicity can reduce JAK inhibitor effectiveness, limiting broader adoption of certain combination therapies.

High Treatment Cost and Unequal Reimbursement Access

Unequal reimbursement continues to limit treatment access across Asia-Pacific, South America, the Middle East, and Africa. In 2024, Canada’s Drug Agency assessed momelotinib at an incremental cost-effectiveness ratio of USD 245,628 per quality-adjusted life year gained and stated that its price should not exceed the least costly reimbursed JAK inhibitor. While ruxolitinib’s inclusion on China’s National Reimbursement Drug List reduced annual costs and expanded access, newer agents have limited public reimbursement in many Asian markets. Limited health economic evidence based on validated quality-adjusted life year outcomes remains a barrier to higher-priced combination regimens outside the United States.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Disease Type: Secondary Myelofibrosis Supports a Growing Long-Term Opportunity

Primary myelofibrosis held 55.67% of the myelofibrosis treatment market share by disease type in 2025, driven by higher de novo incidence than post-essential thrombocythemia and post-polycythemia vera forms. It also remains the established focus of diagnosis and initial treatment. Secondary myelofibrosis is forecast to grow at a 9.22% CAGR through 2031 as longer survival among patients with essential thrombocythemia and polycythemia vera increases the population at risk of transformation. Hydroxyurea and pegylated interferon support long-term disease management, increasing the need for transformation monitoring.

Advances in molecular diagnosis and risk classification support the secondary myelofibrosis segment. A 2026 study from an Indian tertiary referral cohort found that upfront 69-gene next-generation sequencing reclassified 16.4% of patients with myeloproliferative neoplasms into higher prognostic risk categories. The MYSEC-PM score supports risk-based therapy selection for post-myeloproliferative neoplasm secondary myelofibrosis and is used in European treatment algorithms, with increasing adoption across Asia-Pacific specialty centers. These tools improve referral, molecular testing, and timely therapeutic review.

By Drug Class: Combination Programs Test Targeted Therapy’s Front-Line Position

Targeted drug therapy held 58.66% of drug-class revenue in 2025 and includes JAK inhibitors and other molecularly targeted agents. Four approved JAK inhibitors supported the category, while ruxolitinib remained central to front-line symptom and spleen management. The segment reflects a growing focus on matching treatment with anemia and platelet profiles. Emerging targeted combinations are generally being evaluated alongside, rather than in place of, ruxolitinib.

Chemotherapy is forecast to grow at an 8.67% CAGR through 2031, the highest among drug classes. Its use is linked to cytoreductive treatment, particularly hydroxyurea for lower-risk patients in reimbursement-constrained areas of the Asia-Pacific and South America. Pegylated interferon plus ruxolitinib improved marrow cellularity and fibrosis in patients intolerant of prior JAK inhibitor therapy. The Others category includes telomerase inhibitors and MDM2 inhibitors awaiting approval, which could expand the category as Phase 3 programs report results.

By Route of Administration: Oral Treatment Retains Both Scale and Momentum

Oral administration held 57.88% of route-of-administration revenue in 2025 and is forecast to grow at a 9.78% CAGR through 2031. This performance reflects a late-stage pipeline that includes oral candidates such as selinexor, pelabresib, navtemadlin, and AJ1-11095. Oral JAK inhibitors remain the primary option for long-term outpatient care, enabling blood count monitoring and dose adjustments without inpatient admission. This model supports the market's strong outpatient orientation.

The intravenous route serves a smaller but clinically distinct patient group. Imetelstat is administered every 3 weeks for relapsed or refractory disease, and an updated post-hoc analysis presented at ASCO 2026 reported median overall survival of 30.7 months with imetelstat versus 15.4 months with best-available therapy. Subcutaneous and other routes mainly support anemia management, including erythropoiesis-stimulating agents and investigational formulations. Specialty pharmacy networks, monitoring programs, and monthly refill processes further support oral oncology delivery.

By End User: Specialty Clinics Gain as Chronic Care Moves Outside Hospitals

Hospitals held 64.44% of end-user revenue in 2025, reflecting the concentration of high-risk cases requiring inpatient evaluation and management. Bone marrow biopsies, transplant evaluations, and acute cytopenic events often require hospital resources. Academic hospital systems also coordinate multidisciplinary care for allogeneic stem cell transplant candidates. Hospitals, therefore, remain essential for complex clinical needs, despite the shift of routine treatment to outpatient settings.

Specialty hematology and oncology clinics are forecast to expand at a 10.45% CAGR through 2031. Oral JAK inhibitor protocols enable chronic care in dedicated myeloproliferative neoplasm practices, which provide monthly blood count monitoring, dose titration, and symptom assessment. A 2025 real-world analysis examined treatment patterns and healthcare resource use among ruxolitinib-treated patients with myelofibrosis, with and without anemia. Academic medical centers remain important for Phase 3 trials and early adoption, while ambulatory infusion centers support intravenous treatments, particularly imetelstat.

Geography Analysis

North America held 42.80% of the myelofibrosis treatment market share in 2025, supported by an estimated 20,000 patients in the United States and access to all four FDA-approved JAK inhibitors. Restricted specialty pharmacies support treatment distribution and monitoring. Europe is the second-largest regional market, with ruxolitinib, momelotinib, and fedratinib authorized through the European Medicines Agency’s centralized route. Germany, the United Kingdom, and France lead regional volumes through designated myeloproliferative neoplasm expert centers, while country-specific reimbursement often requires clinical and health economic evidence.

Asia-Pacific is forecast to grow at an 8.95% CAGR through 2031. China’s National Medical Products Administration approved TQ05105, branded Anxu, on February 28, 2026, as a dual JAK/ROCK inhibitor for eligible adults with primary and secondary myelofibrosis; registration data showed SVR35 in 58.33% of patients and TSS50 in 77.78% of patients. China’s myelofibrosis patient population exceeded 67,000 in 2025 and is projected to approach 300,000 by 2030, supported by diagnostic capacity, aging demographics, and tertiary hematology infrastructure. Japan supports steady JAK inhibitor use, while India’s 2026 69-gene sequencing study reclassified 16.4% of patients into higher prognostic risk groups, supporting earlier specialist care.

The Middle East and Africa remain at an early commercial stage for JAK inhibitor therapy, with treatment concentrated in tertiary oncology centers across GCC countries, South Africa, and other major urban locations. Limited reimbursement infrastructure requires many patients to rely on hospital formularies or manufacturer support programs. Brazil and Argentina lead South American activity, although cost and access constraints persist, while Brazil’s public health system is beginning to incorporate treatment pathways as awareness expands beyond academic centers. Diagnostic expansion, international trial participation, and stronger specialist referral networks support gradual adoption across both regions.